Basic Information
Genfit, located in France, is a biopharmaceutical company dedicated to developing drugs for the treatment and prevention of cardiometabolic and neurodegenerative diseases. The company focuses on various diseases such as diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer's disease, among others. Elafibranor is one of its leading drug candidates. Elafibranor is a dual agonist of PPAR-α and PPAR-δ (proteins involved in cellular metabolism) and is used for the treatment of NASH (non-alcoholic steatohepatitis). Research has found that Elafibranor is effective in treating NASH with safety and tolerability, without side effects such as weight gain, edema, or fluid retention. Elafibranor can also be used to treat primary biliary cholangitis (PBC).